AOUS Le Scotte

Siena 53100

0 studies enrolling now · 2 studies all time

What they study most

Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN), Merkel Cell Carcinoma, Relapsed or Refractory Acute Myeloid Leukemia (AML)

Studies at this site

• An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) — Stopped early
• Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma — Status unconfirmed